XIG: FHIR Resources

FHIR IG Statistics: FHIR Resources

Version: All | R2 | R2B | R3 | R4 | R4B | R5 | R6
Authority: All | hl7 | ihe | national
Realm: All | BNW | au | be | br | ca | ch | cl | cr | cz | de | dk | ee | eu | fi | fr | il | in | it | jp | nl | no | nz | pt | se | sl | stt | tw | uk | us | uv | vn
View: All | Resource Profiles | Datatype Profiles | Extensions | Logical Models | CodeSystems | ValueSets | ConceptMaps

Resources - All Kinds, Realm US

18,267 resources

By Version

R2: 52
R2B: 0
R3: 523
R4: 17,252
R4B: 0
R5: 440
R6: 0

By Authority

none: 1,998
hl7: 16,267
national: 2

Start Prev Rows 10600 - 10800 Next

Package	Version	Identity	Name/Title	Status	Date	Auth
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.33	Galactosemia	active	2024-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.330	Venous Thromboembolism	active	2025-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.331	Urological Surgery	active	2024-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.333	Urological Surgery	active	2025-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.335	Obstetrical or Pregnancy Related Conditions	active	2024-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.337	Obstetrical or Pregnancy Related Conditions	active	2025-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.338	Obstetrics VTE	active	2021-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.340	Obstetrics VTE	active	2024-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.344	Intracranial Neurosurgery	active	2021-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.346	Intracranial Neurosurgery	active	2025-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.348	General or Neuraxial Anesthesia	active	2021-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.35	Galactosemia	active	2021-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.361	General Surgery	active	2021-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.365	General Surgery	active	2025-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.367	Cesarean Birth	active	2021-06	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.369	Cesarean Birth	active	2025-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.37	Parenteral Nutrition	active	2021-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.38	Parenteral Nutrition	active	2022-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.384	Medical Induction of Labor	active	2024-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.393	Conditions Possibly Justifying Elective Delivery Prior to 39 Weeks Gestation	active	2024-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.395	Conditions Possibly Justifying Elective Delivery Prior to 39 Weeks Gestation	active	2025-05	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.400	Low Risk	active	2024-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.401	Delivery Procedures	active	2025-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.418	Classical Cesarean Birth	active	2024-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.419	Classical Cesarean Birth	active	2021-06	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.421	Classical Cesarean Birth	active	2022-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.422	Myomectomy	active	2024-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.423	Statin Allergen	active	2021-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.424	Nonelective Inpatient Encounter	active	2025-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.473	Medical Reason For Not Providing Treatment	active	2022-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.75	Neonatal Intensive Care Unit	active	2021-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.76	Single Live born Newborn	active	2021-06	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.78	Galactosemia	active	2021-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.79	Parenteral Nutrition	active	2021-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.87	Discharge To Acute Care Facility	active	2021-06	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.117.1.7.1.93	Patient Refusal	active	2025-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1434.1047	Skin Melanoma pT1	active	2024-10	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.100	Injectable Fluorouracil	active	2020-09	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.101	Trastuzumab and Biosimilars	active	2023-07	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.102	Breast Cancer	active	2020-10	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.103	HER2 Presence in Tissue	active	2020-09	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.104	Depression Screening for Adult	active	2020-10	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.105	Long Acting Opioids	active	2024-08	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.106	High Fiber Supplement or Diet Education	active	2020-10	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.107	Standardized Assessment Tools for Dyspnea	active	2020-10	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.108	Nausea or Vomiting Assessment	active	2020-10	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.109	Pancreatic Cancer	active	2020-10	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.110	Pancreatic Cancer	active	2023-07	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.111	Audio Visual Telehealth Encounter	active	2020-10	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.112	Telephone Encounter	active	2020-10	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.113	Telehealth Emergency Department or Initial Inpatient	active	2020-10	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.114	Karnofsky Performance Status	active	2020-10	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.115	Referral to Hospice Care	active	2020-10	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.116	Referral to Palliative Care	active	2020-10	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.117	Assessment Scale for Dyspnea	active	2020-10	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.118	Nausea or Vomiting Assessment	active	2020-10	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.119	Enrollment in Hospice Care	active	2020-10	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.120	Palliative Care	active	2020-10	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.121	Advance Directive Including Durable Power of Attorney or Instructional	active	2020-10	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.122	Carmustine Injectable	active	2022-09	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.123	Dacarbazine Injectable	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.124	Streptozocin Injectable	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.126	Alemtuzumab Injectable	active	2024-11	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.127	Azacitidine Injectable	active	2024-11	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.128	Bendamustine Injectable	active	2024-11	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.129	Busulfan Injectable	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.130	Temozolomide Injectable	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.131	Thiotepa Injectable	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.132	Oxaliplatin Injectable	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.133	Romidepsin Injectable	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.134	Trabectedin Injectable	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.135	Dolasetron Oral	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.136	Dolasetron Injectable	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.137	Granisetron Oral	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.138	Granisetron Transdermal	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.139	Granisetron Injectable	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.140	Ondansetron Oral	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.141	Ondansetron Injectable	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.142	Ifosfamide Injectable	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.143	Arsenic Trioxide Injectable	active	2024-11	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.144	Netupitant Palonosetron Oral	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.145	Fosnetupitant Palonosetron Injectable	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.146	Aprepitant Injectable	active	2024-11	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.147	Rolapitant Injectable	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.148	Dexamethasone Oral	active	2022-09	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.149	Dexamethasone Injectable	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.150	Dexamethasone Drug Implant	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.151	Olanzapine Oral	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.152	Olanzapine Injectable	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.153	Idarubicin Injectable	active	2024-11	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.154	Neurokinin 1 Receptor Antagonist Ingredient	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.155	Serotonin Receptor Antagonist Ingredient	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.156	Clofarabine Injectable	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.157	Belinostat Injectable	active	2024-11	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.158	Bortezomib Injectable	active	2024-11	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.159	Cabazitaxel Injectable	active	2021-05	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.160	Carfilzomib Injectable	active	2021-05	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.161	Decitabine Injectable	active	2021-05	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.162	Elotuzumab Injectable	active	2021-05	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.163	Enfortumab Injectable	active	2021-05	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.164	Eribulin Injectable	active	2021-05	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.165	Etoposide Injectable	active	2021-05	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.166	Inotuzumab Ozogamicin Injectable	active	2021-05	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.167	Mitoxantrone Injectable	active	2024-11	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.168	Moxetumomab Injectable	active	2021-05	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.169	Necitumumab Injectable	active	2021-05	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.170	Nelarabine Injectable	active	2021-05	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.171	Temsirolimus Injectable	active	2021-05	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.172	Tisagenlecleucel Injectable	active	2021-05	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.173	Topotecan Injectable	active	2021-05	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.178	Atezolizumab Injectable	active	2024-11	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.179	Avelumab Injectable	active	2024-11	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.180	Bleomycin Injectable	active	2024-11	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.181	Cemiplimab Injectable	active	2024-11	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.182	Cladribine Injectable	active	2021-05	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.183	Daratumumab Injectable	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.184	Durvalumab Injectable	active	2024-11	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.185	Emapalumab Injectable	active	2024-11	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.186	Fludarabine Injectable	active	2021-05	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.187	Ipilimumab Injectable	active	2024-11	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.188	Nivolumab Injectable	active	2024-11	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.189	Pembrolizumab Injectable	active	2024-12	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.190	Polatuzumab Vedotin Injectable	active	2021-07	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.191	Pralatrexate Injectable	active	2021-07	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.192	Vincristine Injectable	active	2021-07	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.193	Methotrexate Injectable	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.194	Trastuzumab Injectable	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.195	Mitomycin Injectable	active	2021-05	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.196	Brentuximab Vedotin Injectable	active	2021-05	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.197	Doxorubicin Pegylated Liposomal Injectable	active	2024-11	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.198	Blinatumomab Injectable	active	2024-11	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.199	Trastuzumab Emtansine Injectable	active	2021-05	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.200	Gemtuzumab Ozogamicin Injectable	active	2021-05	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.201	Tagraxofusp Injectable	active	2024-12	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.202	Axicabtagene Ciloleucel Injectable	active	2024-11	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.203	BRCA1	active	2023-06	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.204	BRCA2	active	2023-06	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.205	BRCA1 Testing	active	2023-06	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.207	Epithelial Ovarian Cancer	active	2024-08	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.208	Primary Peritoneal Cancer	active	2022-06	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.209	Fallopian Tube Cancer	active	2022-06	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.210	Multigene Panel	active	2023-07	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.211	BRCA1 and BRCA2	active	2023-06	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.212	BRCA1 and BRCA2 Testing	active	2023-06	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.213	BRAF V600	active	2022-01	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.214	BRAF V600 Testing	active	2023-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.215	Colorectal Cancer	active	2024-08	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.216	BRAF V600 Mutation Status	active	2022-01	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.217	Cancer Stage I	active	2024-08	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.218	Head and Neck Cancer	active	2022-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.219	Malignant Melanoma of Skin	active	2022-06	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.220	Brain Cancer	active	2022-07	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.221	Waldenstrom Macroglobulinemia	active	2024-08	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.222	High Emetic Risk Intravenous Antineoplastic Agent	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.223	Moderate Emetic Risk Intravenous Antineoplastic Agent	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.224	Docetaxel Injectable	active	2024-12	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.225	Cyclophosphamide Injectable	active	2022-09	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.226	LAG 3 Inhibitor	active	2024-11	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.233	Chemotherapy Administration	active	2024-01	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.240	Pathological N Stage N3c	active	2024-09	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.241	Audio Visual Telehealth Encounter	active	2025-01	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.242	Moderate or High Emetic Risk Oral Antineoplastic Agent	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.243	Minimal to Low Emetic Risk Oral Antineoplastic Agent	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.244	Copanlisib Injectable	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.245	Isatuximab Injectable	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.246	Loncastuximab tesirine Injectable	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.247	Margetuximab Injectable	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.248	Mirvetuximab soravtansine Injectable	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.249	Tafasitamab Injectable	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.250	Teclistamab Injectable	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.251	Tisotumab Injectable	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.252	Asparaginase Injectable	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.254	Belantamab Injectable	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.255	Dostarlimab Injectable	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.256	Mosunetuzumab Injectable	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.257	Tremelimumab Injectable	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.258	Indication for Dexamethasone	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.260	Indication for Olanzapine	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.261	Indication for Dexamethasone	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.263	Indication for Olanzapine	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.264	Prednisone	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.265	As Needed PRN	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.3.266	Amivantamab Injectable	active	2025-04	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.200	Doxorubicin	active	2020-09	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.201	Epirubicin	active	2020-09	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.202	Capecitabine	active	2023-06	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.203	Cyclophosphamide	active	2020-09	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.204	Injectable Fluorouracil	active	2020-09	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.205	Methotrexate	active	2020-09	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.206	Trastuzumab and Biosimilars	active	2020-09	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.207	HER2 Presence in Tissue	active	2022-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.208	Carboplatin	active	2020-09	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.209	Depression Screening for Adult	active	2022-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.210	Long Acting Opioids	active	2020-10	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.211	High Fiber Supplement or Diet Education	active	2022-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.212	Dexamethasone	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.213	Olanzapine	active	2021-03	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.214	Pancreatic Cancer	active	2020-10	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.215	Audio Visual Telehealth Encounter	active	2025-02	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113883.3.1444.5.216	Telephone Encounter	active	2022-03	hl7